Cox Christopher Nixon 4
Research Summary
AI-generated summary
Alto Neuroscience Director Christopher Cox Receives Option Award
What Happened
Christopher Nixon Cox, a member of the board of Alto Neuroscience, was granted a derivative award (option) to acquire 10,958 shares on 2026-05-12. The option has an exercise price of $0.00 (no cash paid by the reporting person) and was issued as director compensation rather than bought on the open market.
Key Details
- Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (appears timely).
- Security: Option/derivative to acquire 10,958 shares; exercise price $0.00.
- Vesting: Options vest on the earlier of the one-year anniversary of grant or the Issuer's next Annual Meeting, subject to continuous service (Footnote F1).
- Consideration: Award was issued under the Non-Employee Director Compensation Policy and was not purchased by the director (no consideration paid) (Footnote F2).
- Shares owned after the transaction: not specified in the provided filing excerpt.
Context
This was a compensation grant to a non-employee director (routine for board pay), not a market purchase or sale. As a derivative award, the shares become meaningful only if/when the option vests and is exercised; it does not indicate an immediate sale or acquisition of common stock.